Ticker Details
Fate Therapeutics, Inc. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders.
IPO Date:	October 1, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$147.65M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.55 | 3.56%
Avg Daily Range (30 D):	$0.04 | 3.15%
Avg Daily Range (90 D):	$0.04 | 3.66%

Institutional Daily Volume
Avg Daily Volume:	.93M
Avg Daily Volume (30 D):	1.28M
Avg Daily Volume (90 D):	1.43M

Trade Size
Avg Trade Size (Sh.):	119
Avg Trade Size (Sh.) (30 D):	217
Avg Trade Size (Sh.) (90 D):	258

Institutional Trades
Total Institutional Trades:	3,465
Avg Institutional Trade:	$2.74M
Avg Institutional Trade (30 D):	$1.18M
Avg Institutional Trade (90 D):	$1.19M
Avg Institutional Trade Volume:	.14M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.79M
Avg Closing Trade (30 D):	$1.2M
Avg Closing Trade (90 D):	$1.2M
Avg Closing Volume:	204.96K

News

Mar 27, 2026 @ 1:15 PM Scalable Biotech Manufacturing Unlocks a $14B Mark... Source: Usanewsgroup.Com News Commentary

Mar 3, 2026 @ 3:02 PM Cell Therapies Moving From Lab to Factory Floor, a... Source: Prnewswire

Feb 16, 2026 @ 6:00 PM IPSC-derived NK Cells Clinical Trial Pipeline Gain... Source: Delveinsight

Jan 23, 2026 @ 5:56 PM Breaking Barriers: How 2026’s Top Clinical ... Source: Equity Insider

Oct 26, 2025 @ 3:30 PM Fate Therapeutics Presents New Clinical Data at AC... Source: Fate Therapeutics

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.15	$-.27	$-1.15
Diluted EPS	$-1.15	$-.27	$-1.15
Revenue	$6.65M	$1.37M	$6.65M
Gross Profit
Net Income / Loss	$-136.32M	$-32.37M	$-136.32M
Operating Income / Loss	$-147.7M	$-34.72M	$-147.7M
Cost of Revenue
Net Cash Flow	$10.57M	$6.01M	$10.57M
PE Ratio